Regeneron (NASDAQ:REGN) had its target price trimmed by Credit Suisse Group from $440.00 to $420.00 in a research report released on Tuesday. The firm currently has a buy rating on the biopharmaceutical company’s stock.
A number of other equities research analysts have also recently commented on the company. JPMorgan Chase increased their price target on Regeneron from $455.00 to $457.00 and gave the company a neutral rating in a research note on Wednesday, January 24th. Zacks Investment Research cut Regeneron from a hold rating to a sell rating in a research note on Monday, February 5th. UBS cut Regeneron from an outperform rating to a market perform rating in a research note on Monday, April 9th. Argus decreased their price target on Regeneron from $540.00 to $470.00 and set a buy rating for the company in a research note on Thursday, December 28th. Finally, Canaccord Genuity reiterated a buy rating and issued a $522.00 price target on shares of Regeneron in a research note on Wednesday, February 7th. Four research analysts have rated the stock with a sell rating, seventeen have assigned a hold rating and eight have issued a buy rating to the company’s stock. Regeneron currently has an average rating of Hold and a consensus price target of $448.72.
Shares of NASDAQ REGN opened at $315.55 on Tuesday. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.82 and a quick ratio of 3.18. The firm has a market cap of $34,612.42, a P/E ratio of 23.25, a P/E/G ratio of 1.04 and a beta of 1.46. Regeneron has a 1-year low of $313.53 and a 1-year high of $543.55.
In related news, Director Joseph L. Goldstein sold 2,000 shares of the firm’s stock in a transaction dated Monday, March 19th. The stock was sold at an average price of $350.02, for a total transaction of $700,040.00. Following the sale, the director now directly owns 14,000 shares of the company’s stock, valued at $4,900,280. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Joseph L. Goldstein sold 1,000 shares of the firm’s stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $325.60, for a total value of $325,600.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 5,000 shares of company stock worth $1,705,640. 10.80% of the stock is owned by corporate insiders.
A number of institutional investors have recently bought and sold shares of REGN. Dimensional Fund Advisors LP grew its holdings in Regeneron by 0.4% during the third quarter. Dimensional Fund Advisors LP now owns 161,491 shares of the biopharmaceutical company’s stock worth $72,193,000 after acquiring an additional 633 shares during the period. Vident Investment Advisory LLC acquired a new stake in Regeneron during the third quarter worth about $200,000. Atlantic Trust Group LLC acquired a new stake in Regeneron during the third quarter worth about $3,560,000. DnB Asset Management AS acquired a new stake in Regeneron during the fourth quarter worth about $9,136,000. Finally, Atria Investments LLC grew its holdings in Regeneron by 50.4% during the fourth quarter. Atria Investments LLC now owns 1,930 shares of the biopharmaceutical company’s stock worth $726,000 after acquiring an additional 647 shares during the period. 66.40% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This report was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://stocknewstimes.com/2018/04/20/regeneron-regn-pt-lowered-to-420-00-at-credit-suisse-group.html.
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Receive News & Ratings for Regeneron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron and related companies with MarketBeat.com's FREE daily email newsletter.